Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.99 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 222.25K shares, a 19.95% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.77M shares, a 35.88% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 12.00K shares, a 52.00% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 45.00K shares.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.37M shares, a 52.64% increase from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.56M shares, a 35.50% decline from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.41M shares, a 96.42% increase from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.23M shares, a 15.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 222.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 2.99M shares 10-Q · filed 2026-08-05 | 3.01M shares derived: sum of 3 quarters · filed 2026-08-05 | 3.05M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 2.77M shares 10-Q · filed 2026-05-15 | 2.78M shares derived: sum of 2 quarters · filed 2026-05-15 | 2.83M shares derived: sum of 3 quarters · filed 2026-05-15 | 3.11M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 57.00K shares derived: sum of 2 quarters · filed 2026-03-06 | 334.65K shares derived: sum of 3 quarters · filed 2026-03-06 | 2.37M shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 45.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 322.65K shares derived: sum of 2 quarters · filed 2025-11-12 | 2.36M shares 10-Q · filed 2025-11-12 | 2.39M shares derived: sum of 4 quarters · filed 2026-03-06 |
| 2025-06-30 | 277.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 2.32M shares 10-Q · filed 2025-08-13 | 2.34M shares derived: sum of 3 quarters · filed 2026-03-06 | 2.34M shares derived: sum of 4 quarters · filed 2026-03-06 |
| 2025-03-31 | 2.04M shares 10-Q · filed 2025-05-05 | 2.06M shares derived: sum of 2 quarters · filed 2026-03-06 | 2.06M shares derived: sum of 3 quarters · filed 2026-03-06 | 2.32M shares derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 25.00K shares derived: sum of 2 quarters · filed 2026-03-06 | 276.34K shares derived: sum of 3 quarters · filed 2026-03-06 | 1.56M shares 10-K · filed 2026-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 251.34K shares derived: sum of 2 quarters · filed 2024-11-13 | 1.53M shares 10-Q · filed 2024-11-13 | 1.67M shares derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | 251.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 1.53M shares 10-Q · filed 2024-08-06 | 1.67M shares derived: sum of 3 quarters · filed 2025-03-20 | 1.72M shares derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | 1.28M shares 10-Q · filed 2024-05-07 | 1.42M shares derived: sum of 2 quarters · filed 2025-03-20 | 1.47M shares derived: sum of 3 quarters · filed 2025-03-20 | 1.71M shares derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | 142.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 189.00K shares derived: sum of 2 quarters · filed 2025-03-20 | 431.66K shares derived: sum of 3 quarters · filed 2025-03-20 | 2.41M shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 47.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 289.66K shares derived: sum of 2 quarters · filed 2023-11-09 | 2.27M shares 10-Q · filed 2023-11-09 | 2.40M shares derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | 242.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.22M shares 10-Q · filed 2023-08-03 | 2.35M shares derived: sum of 3 quarters · filed 2024-03-01 | 2.38M shares derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | 1.98M shares 10-Q · filed 2023-05-04 | 2.11M shares derived: sum of 2 quarters · filed 2024-03-01 | 2.14M shares derived: sum of 3 quarters · filed 2024-03-01 | 2.27M shares derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | 128.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | 160.40K shares derived: sum of 2 quarters · filed 2024-03-01 | 285.79K shares derived: sum of 3 quarters · filed 2024-03-01 | 1.23M shares 10-K · filed 2024-03-01 |
| 2022-09-30 | 32.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 157.78K shares derived: sum of 2 quarters · filed 2022-11-10 | 1.10M shares 10-Q · filed 2022-11-10 | 1.20M shares derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | 125.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 1.07M shares 10-Q · filed 2022-08-10 | 1.17M shares derived: sum of 3 quarters · filed 2023-03-06 | 1.36M shares derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | 942.02K shares 10-Q · filed 2022-05-10 | 1.04M shares derived: sum of 2 quarters · filed 2023-03-06 | 1.23M shares derived: sum of 3 quarters · filed 2023-03-06 | |
| 2021-12-31 | 98.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 291.57K shares derived: sum of 2 quarters · filed 2023-03-06 | 1.45M shares 10-K · filed 2023-03-06 | |
| 2021-09-30 | 192.77K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 1.35M shares 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | 1.16M shares 10-Q · filed 2021-09-09 | |||
| 2020-12-31 | 6.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 57.43K shares derived: sum of 2 quarters · filed 2022-03-10 | 343.17K shares 10-K · filed 2022-03-10 | |
| 2020-09-30 | 50.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 336.63K shares 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | 285.74K shares 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |